<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751646</url>
  </required_header>
  <id_info>
    <org_study_id>ATN 109 Version 2.0</org_study_id>
    <nct_id>NCT01751646</nct_id>
  </id_info>
  <brief_title>Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy (cART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of
      adolescents and young adults with HIV infection in the Adolescent Medicine Trials Network for
      HIV/AIDS Interventions (ATN) who are currently being treated with cART that includes
      tenofovir disoproxil fumarate (TDF) as one component of the regimen that includes at least
      three Food and Drug Administration (FDA)-approved antiretroviral (ARV) drugs for at least 180
      days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48 week randomized double-blind, placebo-controlled prospective cohort study of
      adolescents and young adults with HIV infection in the ATN who are currently being treated
      with cART that includes TDF as one component of the regimen that includes at least three Food
      and Drug Administration (FDA)-approved ARVs for at least 180 days. Subjects must have at
      least one documented viral load that is below 200 copies/mL that is collected following
      initiation of TDF containing cART and greater than 90 days prior to randomization; no viral
      load above 200 copies/mL if measured within the 90 days prior to randomization; and an HIV
      viral load obtained at screening that is below 200 copies/mL.

      Treatment assignments will be balanced by subject sex at birth, age (&lt;20 years vs. &gt;=20
      years), and race (African American vs. other). Enrolled subjects will be randomized to
      receive vitamin D3 50000 IU or matching placebo, given orally every four weeks by DOT. In
      addition to the randomized study agent, all subjects will receive a MVI to be taken orally
      once daily. This &quot;standard&quot; MVI will contain ingredients not to exceed 600 IU of vitamin D3
      and 200 mg Ca.

      Dual energy x-ray absorptiometry (DXA) measurement of bone mineral content (BMC)/bone mineral
      density (BMD) of whole body, spine, and hip, will be performed at baseline and study weeks 24
      and 48. Blood and urine sampling to assess the Ca-phosphorous (PO4) axis, parathyroid hormone
      (PTH)-FGF23-vitamin D signaling, bone turnover, and renal glomerular and tubular function
      will occur at baseline and study weeks 12, 24, and 48. Blood samples to measure Gluc
      homeostasis will be drawn at baseline and week 48, and will be run by batch analysis.

      Safety, measured by serum calcium (SCa) and serum creatinine (SCr), will be monitored by
      subject's record review at study sites since these labs will generally be measured as a part
      of routine clinical care. The Adolescent Medicine Trials Network for HIV/AIDS Interventions
      109 (ATN 109) study will use the SCa and SCr values obtained within 10 weeks at the time of
      the visit beginning at the baseline visit. If these evaluations were not performed within the
      prior 10 weeks they will be drawn at the time of each visit. Viral load and cluster of
      differentiation 4 (CD4) cell count results will be recorded for this study, ATN 109, at
      screening, baseline and study weeks 12, 24, 48, and Post-Week 48 provided the evaluations
      were done within the protocol specified timeframe. If the evaluations were not performed
      within the protocol specified timeframes they will be drawn at the time of the visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>Percent change from baseline to week (wk) 48 in DXA-measured BMD at the spine for the randomized study groups.
Lumbar spine BMD (L1 - L4) (g/cm2) change from Baseline to wk 48 visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 24 of BMC of Whole Body for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 48 of BMC of Whole Body for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 24 of Femoral Neck BMD for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 48 of Femoral Neck BMD for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 of Femoral Neck BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 of Femoral Neck BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 24 of Total Hip BMD for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 48 of Total Hip BMD for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 of Total Hip BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 of Total Hip BMD Z-score for the Randomized Study Groups</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCr From Baseline to Week 12.</measure>
    <time_frame>Baseline and week 12</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 12 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCr From Baseline to Week 24.</measure>
    <time_frame>Baseline and week 24</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 24 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCr From Baseline to Week 48.</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 48 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Insulin)</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Glucose)</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in Glucose Homeostasis (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR))</measure>
    <time_frame>Baseline and week 48</time_frame>
    <description>HOMA-IR is calculated as fasting glucose (mg/dL) X fasting glucose (uIU/mL) / 405. An increase in HOMA-IR means that an individual has become more resistant (less sensitive) to the effects of insulin and thus would be a negative outcome. A reduction in HOMA-IR means that an individual has become more sensitive to the effects of insulin and would be considered a positive outcome.There are no set minimum or maximum scores for HOMA-IR, since it is based on measurements of insulin and glucose, the assays for which may vary. Several studies suggest a cut-off of &gt;2 for any insulin resistance, but &quot;normal&quot; values appear to vary greatly by population (https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Serum Calcium (SCa)</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Serum Calcium (SCa)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in Serum Calcium (SCa)</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in CTX</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in CTX</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in CTX</measure>
    <time_frame>Baseline and week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in OC</measure>
    <time_frame>Baseline and week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in OC</measure>
    <time_frame>Baseline and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in OC</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in BAP</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in BAP</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in BAP</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in FGF23</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in FGF23</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in FGF23</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in PTH</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in PTH</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in PTH</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Actual Free 1,25-OHD</measure>
    <time_frame>Baseline and wk 12</time_frame>
    <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in Actual Free 1,25-OHD</measure>
    <time_frame>Baseline and wk 24</time_frame>
    <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in Actual Free 1,25-OHD</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in 1,25-OHD</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in 1,25-OHD</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in 1,25-OHD</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in 25-OHD</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in 25-OHD</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in 25-OHD</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in TRP %</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in TRP %</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in TRP %</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in SPO4</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in SPO4</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in SPO4</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in UCa/Ucr</measure>
    <time_frame>Baseline and wk 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 24 in UCa/Ucr</measure>
    <time_frame>Baseline and wk 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 48 in UCa/Ucr</measure>
    <time_frame>Baseline and wk 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated GFR From Baseline to Week 12.</measure>
    <time_frame>Baseline and wk 12</time_frame>
    <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 12 by randomized study group.
eGFR calculated by the CKD-Epi equation for subjects &gt;=18 years of age, and by bedside Schwartz formula for subjects &lt;18 years of age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated GFR From Baseline to Week 24.</measure>
    <time_frame>Baseline and wk 24</time_frame>
    <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 24 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated GFR From Baseline to Week 48.</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 48 by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UGluc From Baseline to Week 48</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>To assess renal tubular function by measuring change in urine glucose (UGluc) by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in URBP/UCr Ratio From Baseline to Week 48</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>To assess renal tubular function by measuring change in urine retinol binding protein to urine creatinine (URBP/UCr) ratio by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UB2MG From Baseline to Week 48</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>To assess renal tubular function by measuring change in urine beta-2 microglobulin (UB2MG) by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in UProt/ UCr Ratio From Baseline to Week 48</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>To assess renal tubular function by measuring change in urinary protein to creatinine ratio by randomized study group;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-OHD Serum Concentration by Randomized Study Group at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-OHD Serum Concentration by Randomized Study Group at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>25-OHD Serum Concentration by Randomized Study Group at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Baseline by Efavirenz Use</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Week 48 by Efavirenz Use</measure>
    <time_frame>Week 48</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Efavirenz Use</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Baseline by Ritonavir Use</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Week 48 by Ritonavir Use</measure>
    <time_frame>Week 48</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Ritonavir Use</measure>
    <time_frame>Baseline and wk 48</time_frame>
    <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Group A: Vitamin D3 50,000 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Vitamin D3 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 50,000 IU</intervention_name>
    <description>Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
    <arm_group_label>Group A: Vitamin D3 50,000 IU</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
    <arm_group_label>Group B: Vitamin D3 placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be considered eligible for enrollment, an individual must meet the criteria listed below
        at the time of randomization:

        NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be
        met prior to performing the DXA scan.

          -  Age 16 years and 0 days to 24 years and 364 days;

          -  Behaviorally infected with HIV (e.g., sexual contact, injection drug use; not infected
             by perinatal transmission, blood transfusion, or at age younger than 9 years);

          -  HIV-1 infection as documented in subject's medical record by at least one of the
             following criteria:

               -  reactive HIV screening test result with an antibody based FDA-licensed assay
                  followed by a positive supplemental assay (e.g., HIV-1 Western Blot, HIV-1
                  Indirect Immunofluorescence, Antibody Differentiation Assay (Multispot)); or

               -  positive HIV-1 DNA polymerase chain reaction (PCR) assay; or

               -  plasma HIV-1 quantitative RNA assay &gt;1,000 copies/mL; or

               -  positive plasma HIV-1 RNA qualitative assay

          -  Subjects must have at least one documented HIV viral load that is below 200 copies/mL
             collected following initiation of TDF containing cART and greater than 90 days prior
             to randomization; no HIV viral load above 200 copies/mL if measured within the 90 days
             prior to randomization; and an HIV viral load obtained at screening that is below 200
             copies/mL.

          -  Currently being treated for at least 180 days by the time of randomization with a TDF
             containing cART with at least 2 other FDA approved ARVs (NOTE: This may include a
             TDF-containing fixed drug combination medication);

          -  Negative serum hepatitis B surface antigen (HBsAg) at screening or by history within 4
             weeks prior to screening (see section 7.1.3);

          -  Willingness and ability to remain on the same cART regimen for the duration of study
             participation;

          -  Willingness and ability to participate in the study, follow all study procedures for
             the duration of study participation, and provide written informed consent or assent
             with parental permission, if applicable; and

          -  For females of child-bearing potential, agreement to use a minimum of one
             proven-effective method of birth control and willingness to postpone pregnancy for the
             duration of study participation (see section 5.3.2 for permitted hormonal
             contraceptives)

        Exclusion Criteria:

        To be considered eligible for enrollment, an individual must not meet any of the criteria
        listed below at the time of randomization:

        NOTE: If the DXA scan is scheduled prior to randomization, all eligibility criteria must be
        met prior to performing the DXA scan.

          -  Prior hypersensitivity to vitamin D;

          -  History of sarcoidosis, arteriosclerosis, renal stones, glomerulonephritis,
             interstitial kidney disease, nephrotic syndrome, hypercalcemia, osteoporosis and/or
             other bone diseases, clinical diagnosis of hypoparathyroidism or hyperparathyroidism;

          -  Lactation or pregnancy currently or within the past 24 weeks;

          -  Chemotherapy or radiation therapy for malignancy within the past 12 months;

          -  Known presence of GI disease that, in the opinion of the clinician, would interfere
             with study agent administration or absorption (e.g. Crohn's, Colitis);

          -  For subjects â‰¥ 18 years, confirmed creatinine clearance &lt; 70 ml/min (estimated
             glomerular filtration rate (GFR) from SCr using Cockcroft and Gault (CG) equation) and
             for subjects &lt;18 years, confirmed creatinine clearance &lt; 70ml/min/1.73m2 (estimated
             GFR from SCr using Schwartz formula (see section 3.5). (Estimated GFR may be
             calculated using the formulae programmed on the ATN website);

          -  SCa &gt; Upper Limit Normal (ULN) for local laboratory values (see section 7.1.3);

          -  Active Grade 3 or higher clinical or laboratory toxicity except atazanavir (ATV)
             associated indirect hyperbilirubinemia (see section 9.5.2.2);

          -  Weight is &gt; 350 pounds (lbs) or 159 kilograms (kgs);

          -  Positive hepatitis C antibody by history or at screening (see section 7.1.3); and

          -  Use of any medications as specified in sections 5.3.1, 5.3.3 and 5.4.

          -  Females Only: Use of certain hormonal contraceptives as specified in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>24 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Havens, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MACC Fund Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hopsital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California - NICHD Westat Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Diagnostic and Treatment Center - NICHD Westat Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stroger Hospital and the CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University - NICHD Westat Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fenway Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Childrens Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital (Puerto Rico) - NICHD Westat Site</name>
      <address>
        <city>San Juan</city>
        <zip>00936-5067</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.atnonline.org</url>
    <description>ATN website</description>
  </link>
  <results_reference>
    <citation>Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial. Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753.</citation>
    <PMID>29020329</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <results_first_submitted>October 18, 2017</results_first_submitted>
  <results_first_submitted_qc>November 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2019</results_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This research was conducted at 17 clinical sites, with accrual opening 10/2012. Due to budgetary constraints, accrual to protocol Version 1.0 was placed on hold 9/1/2013; follow-up visits for subjects on study continued while accrual was on hold. Version 2.0 opened to accrual on 2/2/2015. The study was closed to accrual on 6/3/1015.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Vitamin D3 50,000 IU</title>
          <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
        </group>
        <group group_id="P2">
          <title>Group B: Vitamin D3 Placebo</title>
          <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Starting hormone therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 4 or more consecutive DOT visits</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadvertent enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of the area</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to attend required visits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off study due to multiple obligations</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fails to comply with study requirements</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Childcare issues</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population includes all participants randomized to Group A or Group B who received the intervention, with the exception of two participants (one in each group) who were later determined to have been inadvertent enrollments who did not meet eligibility criteria.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: Vitamin D3 50,000 IU</title>
          <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
        </group>
        <group group_id="B2">
          <title>Group B: Vitamin D3 Placebo</title>
          <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.84" spread="1.95"/>
                    <measurement group_id="B2" value="21.85" spread="1.55"/>
                    <measurement group_id="B3" value="21.84" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-Hispanic or Non-Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown/Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Season Enrolled</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Winter</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spring</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Summer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fall</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar spine bone mineral density (BMD)</title>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" lower_limit="0.99" upper_limit="1.19"/>
                    <measurement group_id="B2" value="1.08" lower_limit="0.98" upper_limit="1.20"/>
                    <measurement group_id="B3" value="1.07" lower_limit="0.99" upper_limit="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lumbar spine BMD (L1-L4) (Z-score)</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.65" lower_limit="-1.40" upper_limit="0.00"/>
                    <measurement group_id="B2" value="-0.70" lower_limit="-1.60" upper_limit="0.20"/>
                    <measurement group_id="B3" value="-0.70" lower_limit="-1.50" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hip BMD</title>
          <population>Subjects with valid DXA data for Total Hip</population>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.06" lower_limit="0.95" upper_limit="1.16"/>
                    <measurement group_id="B2" value="1.05" lower_limit="0.95" upper_limit="1.17"/>
                    <measurement group_id="B3" value="1.06" lower_limit="0.95" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total hip BMD (Z-score)</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects with Total hip BMD z-score data</population>
          <units>Z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.40" lower_limit="-1.10" upper_limit="0.10"/>
                    <measurement group_id="B2" value="-0.65" lower_limit="-1.35" upper_limit="0.00"/>
                    <measurement group_id="B3" value="-0.50" lower_limit="-1.20" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral neck BMD</title>
          <population>Subjects with valid DXA data for Femoral Neck</population>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.98" lower_limit="0.88" upper_limit="1.12"/>
                    <measurement group_id="B2" value="1.00" lower_limit="0.88" upper_limit="1.12"/>
                    <measurement group_id="B3" value="0.99" lower_limit="0.88" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Femoral neck BMD (Z-score)</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects with available Femoral Neck z-score for baseline</population>
          <units>Z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="105"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.50" lower_limit="-1.20" upper_limit="0.30"/>
                    <measurement group_id="B2" value="-0.60" lower_limit="-1.30" upper_limit="0.25"/>
                    <measurement group_id="B3" value="-0.60" lower_limit="-1.20" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Whole Body BMD</title>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.18" lower_limit="1.10" upper_limit="1.25"/>
                    <measurement group_id="B2" value="1.17" lower_limit="1.07" upper_limit="1.26"/>
                    <measurement group_id="B3" value="1.17" lower_limit="1.09" upper_limit="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Whole body BMD (Z-score)</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the whole body, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <units>Z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-0.60" lower_limit="-1.35" upper_limit="0.10"/>
                    <measurement group_id="B2" value="-0.80" lower_limit="-1.65" upper_limit="0.10"/>
                    <measurement group_id="B3" value="-0.70" lower_limit="-1.60" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Whole Body Bone Mineral Content (BMC)</title>
          <units>g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2636.03" lower_limit="2368.41" upper_limit="2938.59"/>
                    <measurement group_id="B2" value="2596.06" lower_limit="2316.00" upper_limit="2936.00"/>
                    <measurement group_id="B3" value="2627.16" lower_limit="2338.39" upper_limit="2938.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Calcium (SCa)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.40" lower_limit="9.22" upper_limit="9.58"/>
                    <measurement group_id="B2" value="9.34" lower_limit="9.14" upper_limit="9.58"/>
                    <measurement group_id="B3" value="9.39" lower_limit="9.16" upper_limit="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urinary Calcium/ Urinary Creatinine ratio (UCa/UCr)</title>
          <population>Subjects with Uca/Ucr lab data available</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.04" lower_limit="0.02" upper_limit="0.07"/>
                    <measurement group_id="B2" value="0.04" lower_limit="0.02" upper_limit="0.07"/>
                    <measurement group_id="B3" value="0.04" lower_limit="0.02" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Phosphate (SPO4)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.56" lower_limit="3.25" upper_limit="3.87"/>
                    <measurement group_id="B2" value="3.50" lower_limit="3.19" upper_limit="3.86"/>
                    <measurement group_id="B3" value="3.52" lower_limit="3.22" upper_limit="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tubular reabsorption of phosphate (TRP) %</title>
          <population>Subjects with TRP % lab data available</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91.72" lower_limit="89.16" upper_limit="93.84"/>
                    <measurement group_id="B2" value="91.53" lower_limit="88.76" upper_limit="94.16"/>
                    <measurement group_id="B3" value="91.56" lower_limit="88.91" upper_limit="93.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitamin D serum concentration (25-(OH)D Total)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.69" lower_limit="12.14" upper_limit="24.89"/>
                    <measurement group_id="B2" value="16.76" lower_limit="10.18" upper_limit="22.68"/>
                    <measurement group_id="B3" value="16.37" lower_limit="11.36" upper_limit="23.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-terminal telopeptides (CTX)</title>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.76" lower_limit="0.56" upper_limit="1.10"/>
                    <measurement group_id="B2" value="0.78" lower_limit="0.59" upper_limit="1.08"/>
                    <measurement group_id="B3" value="0.77" lower_limit="0.58" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parathyroid hormone (PTH)</title>
          <population>Subjects with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.72" lower_limit="28.81" upper_limit="48.52"/>
                    <measurement group_id="B2" value="37.04" lower_limit="28.74" upper_limit="46.55"/>
                    <measurement group_id="B3" value="37.73" lower_limit="28.81" upper_limit="47.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibroblast growth factor 23 (FGF23)</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.23" lower_limit="26.70" upper_limit="42.68"/>
                    <measurement group_id="B2" value="34.53" lower_limit="27.00" upper_limit="42.07"/>
                    <measurement group_id="B3" value="33.99" lower_limit="26.72" upper_limit="42.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 125 dihydroxy vitamin D (125-OHD)</title>
          <population>Subjects with available data</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.54" lower_limit="58.32" upper_limit="89.53"/>
                    <measurement group_id="B2" value="68.94" lower_limit="57.13" upper_limit="96.09"/>
                    <measurement group_id="B3" value="71.08" lower_limit="57.86" upper_limit="93.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Actual Free 125(OH)D</title>
          <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for vitamin D binding protein (VDBP) = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
          <population>Subjects with available data</population>
          <units>fmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="418.48" lower_limit="315.19" upper_limit="638.04"/>
                    <measurement group_id="B2" value="445.29" lower_limit="311.85" upper_limit="638.18"/>
                    <measurement group_id="B3" value="422.91" lower_limit="315.19" upper_limit="638.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine (SCr)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.89" lower_limit="0.76" upper_limit="0.99"/>
                    <measurement group_id="B2" value="0.86" lower_limit="0.76" upper_limit="0.96"/>
                    <measurement group_id="B3" value="0.86" lower_limit="0.76" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated glomerular filtration rate (eGFR)</title>
          <description>Calculated by the chronic kidney disease (CKD)-Epi equation for subjects &gt; =18 years of age; and by bedside Schwartz formula for subjects &lt;18 years of age</description>
          <units>ml/min/1.73m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125.02" lower_limit="114.15" upper_limit="140.02"/>
                    <measurement group_id="B2" value="125.62" lower_limit="112.82" upper_limit="142.16"/>
                    <measurement group_id="B3" value="125.03" lower_limit="112.82" upper_limit="141.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine Glucose (UGluc)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.16" lower_limit="5.13" upper_limit="9.35"/>
                    <measurement group_id="B2" value="7.40" lower_limit="5.46" upper_limit="11.26"/>
                    <measurement group_id="B3" value="7.27" lower_limit="5.34" upper_limit="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine retinol binding protein (URBP)/ Urine creatinine (UCr)</title>
          <population>Subjects with available data</population>
          <units>mcg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101.21" lower_limit="70.14" upper_limit="142.45"/>
                    <measurement group_id="B2" value="104.00" lower_limit="75.93" upper_limit="163.08"/>
                    <measurement group_id="B3" value="101.21" lower_limit="71.63" upper_limit="146.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine beta-2 microglobulin (UB2MG)</title>
          <population>Subjects with available data</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="101"/>
                    <count group_id="B3" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.17" lower_limit="53.28" upper_limit="389.38"/>
                    <measurement group_id="B2" value="134.08" lower_limit="51.91" upper_limit="305.93"/>
                    <measurement group_id="B3" value="127.95" lower_limit="52.59" upper_limit="348.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine protein (UProt) / Urine creatinine (UCr)</title>
          <population>Subjects with available data</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.07" lower_limit="0.05" upper_limit="0.08"/>
                    <measurement group_id="B2" value="0.07" lower_limit="0.05" upper_limit="0.09"/>
                    <measurement group_id="B3" value="0.07" lower_limit="0.05" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone specific alkaline phosphatase (BAP)</title>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.49" lower_limit="25.28" upper_limit="36.74"/>
                    <measurement group_id="B2" value="31.76" lower_limit="25.41" upper_limit="37.94"/>
                    <measurement group_id="B3" value="31.62" lower_limit="25.51" upper_limit="37.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Osteocalcin (OC)</title>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="104"/>
                    <count group_id="B3" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.60" lower_limit="6.47" upper_limit="11.63"/>
                    <measurement group_id="B2" value="8.94" lower_limit="5.97" upper_limit="11.82"/>
                    <measurement group_id="B3" value="9.21" lower_limit="6.20" upper_limit="11.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose Homeostasis (Fasting insulin)</title>
          <population>Subjects with available data</population>
          <units>uIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="108"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="211"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.87" lower_limit="5.57" upper_limit="12.39"/>
                    <measurement group_id="B2" value="8.69" lower_limit="6.05" upper_limit="14.89"/>
                    <measurement group_id="B3" value="8.70" lower_limit="5.59" upper_limit="13.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose Homeostasis (Fasting glucose)</title>
          <population>Subjects with available data</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="103"/>
                    <count group_id="B3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.55" lower_limit="81.15" upper_limit="91.45"/>
                    <measurement group_id="B2" value="86.55" lower_limit="81.05" upper_limit="91.10"/>
                    <measurement group_id="B3" value="85.68" lower_limit="81.05" upper_limit="91.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)</title>
          <description>Calculated as fasting glucose (mg/dL) X fasting insulin (uIU/mL) /405</description>
          <population>Subjects with available data</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="107"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.86" lower_limit="1.07" upper_limit="2.65"/>
                    <measurement group_id="B2" value="1.78" lower_limit="1.26" upper_limit="3.09"/>
                    <measurement group_id="B3" value="1.85" lower_limit="1.19" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups</title>
        <description>Percent change from baseline to week (wk) 48 in DXA-measured BMD at the spine for the randomized study groups.
Lumbar spine BMD (L1 - L4) (g/cm2) change from Baseline to wk 48 visit.</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be greater than the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups</title>
          <description>Percent change from baseline to week (wk) 48 in DXA-measured BMD at the spine for the randomized study groups.
Lumbar spine BMD (L1 - L4) (g/cm2) change from Baseline to wk 48 visit.</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be greater than the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="-1.54" upper_limit="1.48"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-1.49" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1166</p_value>
            <p_value_desc>P-value from Wilcoxon rank sum test for change between baseline and Week 48 Vitamin D vs. Placebo</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 24 of BMC of Whole Body for the Randomized Study Groups</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be greater than the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 24 of BMC of Whole Body for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be greater than the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="-1.23" upper_limit="1.44"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.82" upper_limit="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 48 of BMC of Whole Body for the Randomized Study Groups</title>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 48 of BMC of Whole Body for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-1.47" upper_limit="1.47"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-1.47" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8383</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD for the Randomized Study Groups</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="-0.72" upper_limit="2.16"/>
                    <measurement group_id="O2" value="0.42" lower_limit="-1.02" upper_limit="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the lumbar spine, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-0.30" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1378</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 24 of Femoral Neck BMD for the Randomized Study Groups</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 24 of Femoral Neck BMD for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" lower_limit="-2.49" upper_limit="1.65"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-2.16" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 48 of Femoral Neck BMD for the Randomized Study Groups</title>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 48 of Femoral Neck BMD for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-2.63" upper_limit="1.73"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-2.45" upper_limit="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4686</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 of Femoral Neck BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 of Femoral Neck BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 of Femoral Neck BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 of Femoral Neck BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the femoral neck, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.20" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.20" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7601</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 24 of Total Hip BMD for the Randomized Study Groups</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 24 of Total Hip BMD for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-1.08" upper_limit="1.53"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-1.14" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 48 of Total Hip BMD for the Randomized Study Groups</title>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 48 of Total Hip BMD for the Randomized Study Groups</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-2.12" upper_limit="1.73"/>
                    <measurement group_id="O2" value="-0.42" lower_limit="-1.66" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3978</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 of Total Hip BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 of Total Hip BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 of Total Hip BMD Z-score for the Randomized Study Groups</title>
        <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 of Total Hip BMD Z-score for the Randomized Study Groups</title>
          <description>The Z-score is the standard deviation around mean bone mineral density in the total hip, adjusted for sex, age, and race/ethnicity. An average Z-score of zero would be expected to be seen in healthy populations. A negative Z-score indicates lower than average bone mineral density. Low bone mineral density is a frequent finding in HIV-infected individuals, including adolescents and young adults.</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1187</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SCr From Baseline to Week 12.</title>
        <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 12 by randomized study group;</description>
        <time_frame>Baseline and week 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SCr From Baseline to Week 12.</title>
          <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 12 by randomized study group;</description>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.03" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SCr From Baseline to Week 24.</title>
        <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 24 by randomized study group;</description>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SCr From Baseline to Week 24.</title>
          <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 24 by randomized study group;</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.03" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.04" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SCr From Baseline to Week 48.</title>
        <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 48 by randomized study group;</description>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SCr From Baseline to Week 48.</title>
          <description>To assess renal glomerular safety by measuring change in SCr from baseline to week 48 by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.02" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.03" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5098</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Insulin)</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Insulin)</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>uIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="-2.21" upper_limit="3.48"/>
                    <measurement group_id="O2" value="-0.83" lower_limit="-3.02" upper_limit="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2550</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Glucose)</title>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Glucose)</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="-5.05" upper_limit="4.20"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-4.85" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6499</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in Glucose Homeostasis (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR))</title>
        <description>HOMA-IR is calculated as fasting glucose (mg/dL) X fasting glucose (uIU/mL) / 405. An increase in HOMA-IR means that an individual has become more resistant (less sensitive) to the effects of insulin and thus would be a negative outcome. A reduction in HOMA-IR means that an individual has become more sensitive to the effects of insulin and would be considered a positive outcome.There are no set minimum or maximum scores for HOMA-IR, since it is based on measurements of insulin and glucose, the assays for which may vary. Several studies suggest a cut-off of &gt;2 for any insulin resistance, but &quot;normal&quot; values appear to vary greatly by population (https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance).</description>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in Glucose Homeostasis (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR))</title>
          <description>HOMA-IR is calculated as fasting glucose (mg/dL) X fasting glucose (uIU/mL) / 405. An increase in HOMA-IR means that an individual has become more resistant (less sensitive) to the effects of insulin and thus would be a negative outcome. A reduction in HOMA-IR means that an individual has become more sensitive to the effects of insulin and would be considered a positive outcome.There are no set minimum or maximum scores for HOMA-IR, since it is based on measurements of insulin and glucose, the assays for which may vary. Several studies suggest a cut-off of &gt;2 for any insulin resistance, but &quot;normal&quot; values appear to vary greatly by population (https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance).</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="-0.56" upper_limit="0.82"/>
                    <measurement group_id="O2" value="-0.15" lower_limit="-0.80" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2348</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Serum Calcium (SCa)</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Serum Calcium (SCa)</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" lower_limit="-0.26" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-0.14" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Serum Calcium (SCa)</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Serum Calcium (SCa)</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" lower_limit="-0.26" upper_limit="0.16"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-0.16" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in Serum Calcium (SCa)</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in Serum Calcium (SCa)</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.22" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-0.12" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2648</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in CTX</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in CTX</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.21" upper_limit="0.13"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.19" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in CTX</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in CTX</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.24" upper_limit="0.18"/>
                    <measurement group_id="O2" value="-0.02" lower_limit="-0.16" upper_limit="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in CTX</title>
        <time_frame>Baseline and week 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in CTX</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" lower_limit="-0.25" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.09" lower_limit="-0.27" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3728</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in OC</title>
        <time_frame>Baseline and week 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in OC</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-0.78" upper_limit="1.67"/>
                    <measurement group_id="O2" value="-0.10" lower_limit="-1.15" upper_limit="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in OC</title>
        <time_frame>Baseline and week 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in OC</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the number completed in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-1.06" upper_limit="1.46"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-1.43" upper_limit="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in OC</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in OC</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.93" lower_limit="-2.10" upper_limit="0.62"/>
                    <measurement group_id="O2" value="-0.48" lower_limit="-1.95" upper_limit="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7825</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in BAP</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in BAP</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" lower_limit="-4.33" upper_limit="1.85"/>
                    <measurement group_id="O2" value="-1.74" lower_limit="-3.82" upper_limit="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in BAP</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in BAP</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" lower_limit="-5.31" upper_limit="0.07"/>
                    <measurement group_id="O2" value="-2.03" lower_limit="-4.50" upper_limit="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in BAP</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in BAP</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" lower_limit="-6.44" upper_limit="-0.51"/>
                    <measurement group_id="O2" value="-2.19" lower_limit="-5.58" upper_limit="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1950</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in FGF23</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in FGF23</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="-2.99" upper_limit="9.21"/>
                    <measurement group_id="O2" value="3.90" lower_limit="-2.28" upper_limit="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in FGF23</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in FGF23</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" lower_limit="-4.07" upper_limit="8.35"/>
                    <measurement group_id="O2" value="3.65" lower_limit="-4.45" upper_limit="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in FGF23</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in FGF23</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="-2.78" upper_limit="10.31"/>
                    <measurement group_id="O2" value="3.15" lower_limit="-3.75" upper_limit="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7127</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in PTH</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in PTH</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" lower_limit="-10.26" upper_limit="4.00"/>
                    <measurement group_id="O2" value="-0.82" lower_limit="-7.79" upper_limit="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in PTH</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in PTH</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-10.38" upper_limit="6.70"/>
                    <measurement group_id="O2" value="-1.71" lower_limit="-7.78" upper_limit="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in PTH</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in PTH</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" lower_limit="-10.13" upper_limit="4.25"/>
                    <measurement group_id="O2" value="-0.96" lower_limit="-9.28" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4676</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Actual Free 1,25-OHD</title>
        <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Actual Free 1,25-OHD</title>
          <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>fmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.50" lower_limit="-12.50" upper_limit="222.13"/>
                    <measurement group_id="O2" value="53.23" lower_limit="-28.51" upper_limit="148.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in Actual Free 1,25-OHD</title>
        <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in Actual Free 1,25-OHD</title>
          <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>fmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.61" lower_limit="-29.77" upper_limit="242.62"/>
                    <measurement group_id="O2" value="59.36" lower_limit="-41.94" upper_limit="162.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in Actual Free 1,25-OHD</title>
        <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in Actual Free 1,25-OHD</title>
          <description>Vitamin D serum concentration (1,25 (OH)DTotal) (pmol/L) multiplied by F times 1,000, where F is defined as F = 1/(1 + Kd * [VDBP] + Ka *[albumin]) where the binding constant for VDBP = Kd = 4.2 x 107 M-1, and for albumin is Ka = 5.4 x 104 M-1 and the concentrations of VDBP and albumin are in moles/L</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>fmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.73" lower_limit="-19.39" upper_limit="202.54"/>
                    <measurement group_id="O2" value="25.66" lower_limit="-100.82" upper_limit="118.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0210</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in 1,25-OHD</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in 1,25-OHD</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.61" lower_limit="-0.32" upper_limit="35.18"/>
                    <measurement group_id="O2" value="6.06" lower_limit="-7.63" upper_limit="25.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in 1,25-OHD</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in 1,25-OHD</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.90" lower_limit="-7.57" upper_limit="36.58"/>
                    <measurement group_id="O2" value="8.58" lower_limit="-8.96" upper_limit="27.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in 1,25-OHD</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in 1,25-OHD</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>pg/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.52" lower_limit="-2.05" upper_limit="31.47"/>
                    <measurement group_id="O2" value="2.74" lower_limit="-14.73" upper_limit="24.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in 25-OHD</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in 25-OHD</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.33" lower_limit="9.33" upper_limit="21.19"/>
                    <measurement group_id="O2" value="6.91" lower_limit="2.34" upper_limit="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in 25-OHD</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in 25-OHD</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.60" lower_limit="10.53" upper_limit="25.58"/>
                    <measurement group_id="O2" value="6.78" lower_limit="1.35" upper_limit="11.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in 25-OHD</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in 25-OHD</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/ML</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.80" lower_limit="11.83" upper_limit="24.03"/>
                    <measurement group_id="O2" value="2.64" lower_limit="-1.66" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in TRP %</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in TRP %</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" lower_limit="-3.46" upper_limit="2.03"/>
                    <measurement group_id="O2" value="0.04" lower_limit="-2.78" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in TRP %</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in TRP %</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" lower_limit="-4.43" upper_limit="1.79"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-3.001" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in TRP %</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in TRP %</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" lower_limit="-4.71" upper_limit="1.84"/>
                    <measurement group_id="O2" value="0.62" lower_limit="-2.92" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0814</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in SPO4</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in SPO4</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.34" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.33" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in SPO4</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in SPO4</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-0.42" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.34" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in SPO4</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in SPO4</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.33" upper_limit="0.36"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.47" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4808</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in UCa/Ucr</title>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in UCa/Ucr</title>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.02" upper_limit="0.04"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 24 in UCa/Ucr</title>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 24 in UCa/Ucr</title>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.01" upper_limit="0.05"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.01" upper_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 48 in UCa/Ucr</title>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 48 in UCa/Ucr</title>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.01" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.01" lower_limit="-0.01" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3870</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated GFR From Baseline to Week 12.</title>
        <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 12 by randomized study group.
eGFR calculated by the CKD-Epi equation for subjects &gt;=18 years of age, and by bedside Schwartz formula for subjects &lt;18 years of age</description>
        <time_frame>Baseline and wk 12</time_frame>
        <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated GFR From Baseline to Week 12.</title>
          <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 12 by randomized study group.
eGFR calculated by the CKD-Epi equation for subjects &gt;=18 years of age, and by bedside Schwartz formula for subjects &lt;18 years of age</description>
          <population>Subjects who had baseline and wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ml/min/1.73m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-12.11" upper_limit="6.29"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-7.49" upper_limit="7.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated GFR From Baseline to Week 24.</title>
        <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 24 by randomized study group;</description>
        <time_frame>Baseline and wk 24</time_frame>
        <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated GFR From Baseline to Week 24.</title>
          <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 24 by randomized study group;</description>
          <population>Subjects who had baseline and wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ml/min/1.73m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-15.24" upper_limit="2.43"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-10.42" upper_limit="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated GFR From Baseline to Week 48.</title>
        <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 48 by randomized study group;</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated GFR From Baseline to Week 48.</title>
          <description>To assess renal glomerular safety by measuring change in estimated GFR from baseline to week 48 by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ml/min/1.73m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" lower_limit="-15.67" upper_limit="3.70"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-10.96" upper_limit="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4290</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UGluc From Baseline to Week 48</title>
        <description>To assess renal tubular function by measuring change in urine glucose (UGluc) by randomized study group;</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in UGluc From Baseline to Week 48</title>
          <description>To assess renal tubular function by measuring change in urine glucose (UGluc) by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" lower_limit="-3.27" upper_limit="3.23"/>
                    <measurement group_id="O2" value="-0.43" lower_limit="-3.17" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9186</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in URBP/UCr Ratio From Baseline to Week 48</title>
        <description>To assess renal tubular function by measuring change in urine retinol binding protein to urine creatinine (URBP/UCr) ratio by randomized study group;</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in URBP/UCr Ratio From Baseline to Week 48</title>
          <description>To assess renal tubular function by measuring change in urine retinol binding protein to urine creatinine (URBP/UCr) ratio by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.06" lower_limit="-37.77" upper_limit="32.56"/>
                    <measurement group_id="O2" value="-4.72" lower_limit="-33.97" upper_limit="18.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UB2MG From Baseline to Week 48</title>
        <description>To assess renal tubular function by measuring change in urine beta-2 microglobulin (UB2MG) by randomized study group;</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in UB2MG From Baseline to Week 48</title>
          <description>To assess renal tubular function by measuring change in urine beta-2 microglobulin (UB2MG) by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>mcg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" lower_limit="-95.04" upper_limit="111.85"/>
                    <measurement group_id="O2" value="10.75" lower_limit="-90.69" upper_limit="157.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5810</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in UProt/ UCr Ratio From Baseline to Week 48</title>
        <description>To assess renal tubular function by measuring change in urinary protein to creatinine ratio by randomized study group;</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>Change in UProt/ UCr Ratio From Baseline to Week 48</title>
          <description>To assess renal tubular function by measuring change in urinary protein to creatinine ratio by randomized study group;</description>
          <population>Subjects who had baseline and wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.02" upper_limit="0.01"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.01" upper_limit="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test for change between baseline and Week 48 Group A (Vitamin D3) vs. Group B (Placebo)</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1570</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25-OHD Serum Concentration by Randomized Study Group at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Subjects who had wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>25-OHD Serum Concentration by Randomized Study Group at Week 12</title>
          <population>Subjects who had wk 12 data. This includes subjects enrolled in v1.0, who completed wk 12 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14" lower_limit="29.79" upper_limit="39.76"/>
                    <measurement group_id="O2" value="23.97" lower_limit="18.35" upper_limit="30.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25-OHD Serum Concentration by Randomized Study Group at Week 24</title>
        <time_frame>Week 24</time_frame>
        <population>Subjects who had wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>25-OHD Serum Concentration by Randomized Study Group at Week 24</title>
          <population>Subjects who had wk 24 data. This includes subjects enrolled in v1.0, who completed wk 24 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.04" lower_limit="30.41" upper_limit="44.12"/>
                    <measurement group_id="O2" value="23.30" lower_limit="17.92" upper_limit="28.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>25-OHD Serum Concentration by Randomized Study Group at Week 48</title>
        <time_frame>Week 48</time_frame>
        <population>Subjects who had wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Vitamin D3 50,000 IU</title>
            <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
          </group>
          <group group_id="O2">
            <title>Group B: Vitamin D3 Placebo</title>
            <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
          </group>
        </group_list>
        <measure>
          <title>25-OHD Serum Concentration by Randomized Study Group at Week 48</title>
          <population>Subjects who had wk 48 data. This includes subjects enrolled in v1.0, who completed wk 48 evaluations, but were prematurely discontinued before the wk 96 or Post-wk 48 visits and therefore not counted as having completed the study. Thus, the number analyzed may be different from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.89" lower_limit="30.46" upper_limit="42.38"/>
                    <measurement group_id="O2" value="20.55" lower_limit="14.35" upper_limit="25.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Baseline by Efavirenz Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
        <time_frame>Baseline</time_frame>
        <population>Authors were interested in comparing mean 25-OHD at baseline by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz Use</title>
            <description>Ever used efavirenz</description>
          </group>
          <group group_id="O2">
            <title>No Efavirenz Use</title>
            <description>Never used efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Baseline by Efavirenz Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
          <population>Authors were interested in comparing mean 25-OHD at baseline by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.02" spread="8.69"/>
                    <measurement group_id="O2" value="19.61" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Week 48 by Efavirenz Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
        <time_frame>Week 48</time_frame>
        <population>Authors were interested in comparing mean 25-OHD at wk 48 by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz Use</title>
            <description>Ever used efavirenz</description>
          </group>
          <group group_id="O2">
            <title>No Efavirenz Use</title>
            <description>Never used efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Week 48 by Efavirenz Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
          <population>Authors were interested in comparing mean 25-OHD at wk 48 by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24" spread="11.22"/>
                    <measurement group_id="O2" value="29.68" spread="11.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Efavirenz Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Authors were interested in comparing the change in mean 25-OHD from baseline to wk 48 by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Efavirenz Use</title>
            <description>Ever used efavirenz</description>
          </group>
          <group group_id="O2">
            <title>No Efavirenz Use</title>
            <description>Never used efavirenz</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Efavirenz Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with efavirenz use vs. those without efavirenz use</description>
          <population>Authors were interested in comparing the change in mean 25-OHD from baseline to wk 48 by those who used efavirenz vs those who did not use efavirenz; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.97" spread="12.00"/>
                    <measurement group_id="O2" value="9.79" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of change from baseline to week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of change from baseline to Week 48</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Baseline by Ritonavir Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
        <time_frame>Baseline</time_frame>
        <population>Authors were interested in comparing mean 25-OHD at baseline by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir Use</title>
            <description>Ever used ritonavir</description>
          </group>
          <group group_id="O2">
            <title>No Ritonavir Use</title>
            <description>Never used ritonavir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Baseline by Ritonavir Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
          <population>Authors were interested in comparing mean 25-OHD at baseline by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.62" spread="8.79"/>
                    <measurement group_id="O2" value="18.69" spread="10.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Week 48 by Ritonavir Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
        <time_frame>Week 48</time_frame>
        <population>Authors were interested in comparing mean 25-OHD at wk 48 by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir Use</title>
            <description>Ever used ritonavir</description>
          </group>
          <group group_id="O2">
            <title>No Ritonavir Use</title>
            <description>Never used ritonavir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Week 48 by Ritonavir Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
          <population>Authors were interested in comparing mean 25-OHD at wk 48 by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.46" spread="10.70"/>
                    <measurement group_id="O2" value="28.92" spread="11.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Ritonavir Use</title>
        <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
        <time_frame>Baseline and wk 48</time_frame>
        <population>Authors were interested in comparing the change in mean 25-OHD from baseline to wk 48 by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
        <group_list>
          <group group_id="O1">
            <title>Ritonavir Use</title>
            <description>Ever used ritonavir</description>
          </group>
          <group group_id="O2">
            <title>No Ritonavir Use</title>
            <description>Never used ritonavir</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Ritonavir Use</title>
          <description>Mean Vitamin D serum concentration (25-(OH)D) Total) in those with ritonavir use vs. those without ritonavir use</description>
          <population>Authors were interested in comparing the change in mean 25-OHD from baseline to wk 48 by those who used ritonavir vs those who did not use ritonavir; a separate analysis by treatment arm was not done. Due to different comparison groups, the number of subjects analyzed differ from the numbers in the Participant Flow section.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.55" spread="11.07"/>
                    <measurement group_id="O2" value="10.02" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Test of Week 48 difference from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Test of Week 48 difference from baseline</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected between Baseline through Week 48 or premature discontinuation from study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A: Vitamin D3 50,000 IU</title>
          <description>Subjects randomized to Group A will receive Vitamin D3 50,000 IU orally every four weeks by directly observed therapy (DOT). In addition all subjects receive a multivitamin (MVI) that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Calcium (Ca). Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 50,000 IU: Group A: Vitamin D3 50,000 IU orally every four weeks by DOT</description>
        </group>
        <group group_id="E2">
          <title>Group B: Vitamin D3 Placebo</title>
          <description>Subjects randomized to Group B will receive Vitamin D3 placebo orally every four weeks by DOT. In addition all subjects receive a MVI that contains ingredients not to exceed 600 IU of vitamin D3 and 200 mg of Ca. Subjects will self-administer one MVI tablet orally once daily.
Vitamin D3 placebo: Group B: Vitamin D3 placebo orally every four weeks by DOT</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Cellulitis Streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA SOC</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Streptococcus Test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Adolescent Medicine Trials Network (ATN) for HIV/AIDS Interventions Publication Policy outlines procedures for the development and review of abstracts, publications, and presentations. The Adolescent Medicine Leadership Group (AMLG) retains custody of and primary rights to the data. Use of data must be approved by the protocol team and AMLG.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The analysis by efavirenz use and ritonavir use after baseline do not adjust for treatment group (secondary outcome measures 68, 69, 71, and 72). Results post-baseline may differ based on treatment group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Bob Harris</name_or_title>
      <organization>Westat</organization>
      <phone>301-251-1500</phone>
      <email>bobharris@westat.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

